Prognostic Value of Serum Transferrin Level before Radiotherapy on Radio-Sensitivity and Survival in Patients with Nasopharyngeal Carcinoma

Journal of Personalized Medicine · 8 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This retrospective cohort study analyzed 348 nasopharyngeal carcinoma patients to assess if pre-radiotherapy serum transferrin (TRF) levels predicted treatment response and survival. It found that patients with higher TRF levels had significantly better radio-sensitivity and overall survival than those with lower levels.

Full summary

682 CHARS

A retrospective analysis of 348 nasopharyngeal carcinoma patients treated with IMRT from 2012 to 2016 investigated the prognostic value of pre-treatment serum transferrin (TRF). Patients were divided into high (HTRF) and low (LTRF) TRF groups based on the median level of 2.16 g/L. The study found that a higher pre-radiotherapy TRF level was an independent factor for better radio-sensitivity (OR=1.702, p=0.033) and better overall survival (HR=1.706, p=0.026). The 5-year OS was 78.4% overall, with 84.4% for the HTRF group and 73.1% for the LTRF group. Limitations include its single-center, retrospective design and a lack of experimental validation for the proposed mechanisms.

STUDY TYPE

cohort

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10055805

Prognostic Value of Serum Transferrin Level before Radiotherapy on Radio-Sensitivity and Survival in Patients with Nasopharyngeal Carcinoma

Journal of Personalized Medicine

READ THE FULL PAPER

ABSTRACT

Purpose: To investigate the prognostic value of serum transferrin (TRF) level before intensity-modulated radiation therapy (IMRT) on radio-sensitivity and overall survival (OS) in patients with nasopharyngeal carcinoma (NPC). Methods: From October 2012 to October 2016, a total of 348 patients with NPC in the First Affiliated Hospital of Fujian Medical University were retrospectively analyzed in our study. The concentration of serum TRF was detected by the method of enzyme-linked immunosorbent assay (ELISA). In the whole group, 46 patients received IMRT, and 302 patients received IMRT plus chemotherapy. The radio-sensitive tumor was defined when the local tumor lesions disappeared completely in the nasopharyngeal MRI scan and no tumor residues were found under the electronic nasopharyngoscope one month after the end of radiotherapy. Results: The serum TRF level before IMRT was (1.34–3.89) g/L, with a median of 2.16 g/L and a mean of (2.20 ± 0.42) g/L. In the whole group, 242 cases (69.5%) were radiosensitive, and 106 cases (30.5%) were insensitive. The number of radiosensitive patients in the group of HTRF (transferrin > 2.16 g/L) and LTRF (transferrin ≤ 2.16 g/L) before radiotherapy was 129 (74.6%) and 113 (64.6%), respectively. The difference in radio-sensitivity between the two groups was statistically significant ( χ 2 = 4.103, p = 0.043). Logistic regression analysis showed that the level of TRF before radiotherapy ( OR = 1.702; 95% CI 1.044~2.775; p = 0.033) was an independent factor for radio-sensitivity. The log-rank test showed that patients in the LTRF group achieved a significantly worse OS ( χ 2 = 5.388, p = 0.02) than those in the HTRF group. Cox regression analysis showed that baseline TRF level ( HR = 1.706; 95% CI 1.065~2.731; p = 0.026) was an independent prognostic factor for overall survival. Conclusions: The low level of TRF before IMRT is a risk factor for radio-sensitivity and a prognostic factor for poor OS in NPC patients. It may be a promising marker to predict radio-sensitivity and OS in NPC patients who accept IMRT.

CITATION EXPORT

Yuping Zhan, Li Su, Qiaojing Lin et al.. Prognostic Value of Serum Transferrin Level before Radiotherapy on Radio-Sensitivity and Survival in Patients with Nasopharyngeal Carcinoma. Journal of Personalized Medicine. (2023). https://doi.org/10.3390/jpm13030511

AUTHORS

8 · 3 CENTRES

Yuping Zhan, Li Su, Qiaojing Lin, Xiaoxian Pan, Xiaoxia Li, Weitong Zhou, Weijian Zhang, Jinsheng Hong

1Department of Radiotherapy, First Affiliated Hospital of Fujian Medical University, Chazhong Road #20, Fuzhou 350005, [email protected] (W.Z.)
2National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China
3Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China

EDITOR / REVIEWER

László Mangel